Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma

Cancer Science

Volumn 103, Issue 4, 2012, Pages 739-746

  Shimizu, Atsushi ^a   Hirono, Seiko ^a   Tani, Masaji ^a   Kawai, Manabu ^a   Okada, Ken Ichi ^a   Miyazawa, Motoki ^a   Kitahata, Yuji ^a   Nakamura, Yasushi ^a   Noda, Tetsuo ^b   Yokoyama, Shozo ^a   Yamaue, Hiroki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESOTHELIN; MUCIN; MUCIN 16; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MICROARRAY ANALYSIS; PANCREAS ADENOCARCINOMA; PANCREAS DUCTAL ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; UPREGULATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROGNOSIS; UP-REGULATION;

EID: 84858999573     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02214.x     Document Type: Article

References (35)

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-17.
2. Dumartin L, Quemener C, Laklai H et al. Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. Gastroenterology 2010; 138: 1595-606.
3. Hruban RH, Goggins M, Parsons J Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6: 2969-72.
4. Hruban RH, Adsay NV, Albores-Saavedra J et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001; 25: 579-86.
5. Kern S, Hruban R, Hollingsworth MA et al. A white paper: the product of a pancreas cancer think tank. Cancer Res 2001; 61: 4923-32.
6. Diaz VM, Hurtado M, Thomson TM, Reventos J, Paciucci R. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut 2004; 53: 993-1000.
7. Ceyhan GO, Giese NA, Erkan M et al. The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg 2006; 244: 274-81.
8. Abiatari I, DeOliveira T, Kerkadze V et al. Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol Cancer Ther 2009; 8: 1494-504.
9. Sobin LH, Wittekind CH. International Union Against Cancer: TNM Classification of Malignant Tumors, 6th edn. New York, NY: Wiley and Liss, 2002.
10. Hirono S, Yamaue H, Hoshikawa Y et al. Molecular markers associated with lymph node metastasis in pancreatic ductal adenocarcinoma by genome-wide expression profiling. Cancer Sci 2010; 101: 259-66.
11. McClelland RA, Finlay P, Walker KJ et al. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res 1990; 50: 3545-50.
12. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995; 48: 876-8.
13. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-68.
14. Campagna D, Cope L, Lakkur SS, Henderson C, Laheru D, Iacobuzio-Donahue CA. Gene expression profiles associated with advanced pancreatic cancer. Int J Clin Exp Pathol 2008; 1: 32-43.
15. Fritsche P, Seidler B, Schuler S et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009; 58: 1399-409.
16. Meinhold-Heerlein I, Stenner-Liewen F, Liewen H et al. Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer. Am J Pathol 2001; 158: 1335-44.
17. Seethala RR, Gooding WE, Handler PN et al. Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin Cancer Res 2008; 14: 1303-9.
18. Campbell EJ, McDuff E, Tatarov O et al. Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. Br J Cancer 2008; 99: 1769-74.
19. Cappia S, Righi L, Mirabelli D et al. Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol 2008; 130: 58-64.
20. Ieda J, Yokoyama S, Tamura K et al. Re-expression of CEACAM1 long cytoplasmic domain isoform is associated with invasion and migration of colorectal cancer. Int J Cancer 2011; 129: 1351-61.
21. Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, Urban N. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett 2007; 8: 130-6.
22. Gronborg M, Kristiansen TZ, Iwahori A et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 2006; 5: 157-71.
23. Yamanaka S, Sunamura M, Furukawa T et al. Chromosome 12, frequently deleted in human pancreatic cancer, may encode a tumor-suppressor gene that suppresses angiogenesis. Lab Invest 2004; 84: 1339-51.
24. Rump A, Morikawa Y, Tanaka M et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004; 279: 9190-8.
25. Gubbels JA, Belisle J, Onda M et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006; 5: 50.
26. Japan Pancreas Society. Classification of Pancreatic Carcinoma, 2nd English edn. Tokyo: Kanahara, 2003.
27. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001; 276: 27371-5.
28. O'Brien TJ, Beard JB, Underwood LJ, Shigemasa K. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumor Biol 2002; 23: 154-69.
29. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992; 50: 373-81.
30. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004; 10(12 Pt 1): 3937-42.
31. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003; 27: 1418-28.
32. Argani P, Iacobuzio-Donahue CA, Ryu B et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001; 7: 3862-8.
33. Cheng WF, Huang CY, Chang MC et al. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer 2009; 100: 1144-53.
34. Thériault C, Pinard M, Comamala M et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol 2011; 121: 434-43.
35. Comamala M, Pinard M, Thériault C et al. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signaling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer 2011; 104: 989-99.